What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer
AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.
GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.